新的肺癌药物Zoldonrasib很有前途,61%的病人患有肿瘤萎缩。 New lung cancer drug Zoldonrasib shows promise, with 61% of patients seeing tumor shrinkage.

革命药品分享了关于Zoldonrasib的有希望的初步数据,Zoldonrasib是针对非小细胞肺癌特定突变的新药物。 Revolution Medicines has shared promising initial data on Zoldonrasib, a new drug targeting a specific mutation in non-small cell lung cancer (NSCLC). 该药物在这种突变的患者中表现出良好的安全性和有效性,其中61%患有肿瘤萎缩,89%患有疾病控制。 The drug showed good safety and effectiveness in patients with this mutation, with 61% experiencing tumor shrinkage and 89% seeing disease control. 这些结果在澳大利亚艾滋病理事会年度会议上作了介绍,并建议为癌症难以治疗者提供新的治疗办法。 The results were presented at the AACR Annual Meeting and suggest a new treatment option for those with hard-to-treat cancers.